What is the mechanism of allergic rhinitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mechanism of Allergic Rhinitis

Allergic rhinitis is fundamentally an IgE-mediated inflammatory disease triggered when allergens penetrate the nasal epithelial barrier, initiating a Th2-dominant immune response that produces allergen-specific IgE antibodies and recruits inflammatory cells—particularly mast cells, basophils, and eosinophils—resulting in both immediate and late-phase allergic reactions. 1, 2

Initial Sensitization Phase

The pathogenesis begins with allergen sensitization, a critical first step that occurs before symptoms ever develop:

  • Dendritic cells expressing CD1a and CD11c in the nasal epithelium process inhaled allergens and present allergenic peptides via MHC II molecules to T-cell receptors on resting CD4+ cells in regional lymph nodes 1
  • With appropriate costimulatory signals, these allergen-stimulated T cells proliferate into Th2-biased cells that produce IL-3, IL-4, IL-13, IL-5, and GM-CSF 1
  • This Th2 cytokine profile promotes B-cell isotype switching to produce allergen-specific IgE antibodies by plasma cells, while simultaneously promoting mast cell proliferation and eosinophilic infiltration into the nasal mucosa 1
  • The imbalance between Th2 and Th1 cells, favoring Th2, plays a critical role in regulating IgE synthesis and cell recruitment at sites of allergic inflammation 1

A critical caveat: synthesis of allergen-specific IgE is required for allergic rhinitis development, but many individuals with allergen-specific IgE never develop symptoms, indicating that IgE presence alone is insufficient for disease expression 1

Early-Phase Allergic Response

Upon re-exposure to allergens in sensitized individuals, the immediate reaction occurs within minutes:

  • Cross-linking of IgE antibodies bound to mast cell surfaces by allergen triggers immediate degranulation and release of preformed mediators, primarily histamine, along with tryptase, leukotrienes, and prostaglandins 1, 3, 4
  • Histamine acts predominantly through H1-receptors to induce the characteristic neurally-mediated symptoms: nasal itching, paroxysms of sneezing, and watery rhinorrhea 4
  • Histamine also causes vascular effects leading to nasal congestion, though this is less prominent in the early phase 4
  • Basophils also contribute to histamine generation during this phase 1, 4

Important clinical point: histamine nasal insufflation reproduces all symptoms of allergic rhinitis, and H1-receptor antagonists reduce symptoms by approximately 40-50%, with greatest effect on neurally-mediated responses—demonstrating that histamine is a major but not sole mediator 4

Late-Phase Allergic Response

The late-phase response develops 4 to 8 hours after allergen exposure and involves sustained inflammation:

  • Mast cell-derived cytokines (IL-4, IL-5, IL-6, IL-8, GM-CSF, and RANTES) orchestrate cellular infiltration by upregulating adhesion molecules such as VCAM-1 and E-selectin on endothelial cells 1, 3
  • These adhesion molecules cause circulating eosinophils, basophils, and T-lymphocytes to adhere to endothelial cells before migrating through the endothelium into nasal tissue (diapedesis) 3
  • Tissue infiltration is characterized by CD4+ T-cells, CD25+ T-cells in the submucosa and epithelium, along with activated eosinophils and basophils 1
  • Infiltrating cells release additional mediators including leukotrienes, kinins, and cytokines that perpetuate inflammation 3
  • Leukotrienes are particularly potent mediators of nasal vascular congestion and plasma protein exudation, contributing to anterior nasal secretions 4

The late-phase response is dominated by nasal congestion rather than the sneezing and itching of the early phase 1

Cellular and Molecular Characteristics

The inflammatory infiltrate has distinct features:

  • Eosinophils accumulate in both the lamina propria and epithelium in an activated state, with numbers correlating with pulmonary function abnormalities and bronchial hyperresponsiveness 1, 4
  • Increased numbers of mast cells, T cells, and Langerhans cells (which induce T-cell activation) are found within the epithelium 4
  • Epithelial cells themselves generate chemokines and cytokines that orchestrate cellular recruitment, making them active participants rather than passive barriers 4
  • Recruited eosinophils contribute to their own persistence through autocrine mechanisms 4

Priming Effect

Repeated allergen challenges increase sensitivity over time through a priming effect: the amount of allergen required to induce an immediate response decreases with ongoing exposure due to inflammatory cell influx during repeated late-phase responses 1

This priming phenomenon provides the rationale for initiating anti-inflammatory therapies before the pollen season or before chronic allergen exposures, rather than waiting for symptoms to develop 1

Genetic and Environmental Factors

  • Atopy (the predisposition to develop IgE to common inhaled allergens) has strong familial tendency, typically starting in childhood or adolescence 1
  • Genome-wide searches have identified associations with markers on more than 14 chromosome pairs, though the complex inheritance mechanisms remain incompletely understood 1
  • Environmental factors interact critically with genetic predisposition at the gene-environment interface to determine disease expression 1

Neural Mechanisms

Neuronal reflexes mediate local responses to inflammatory mediators and may participate in T-lymphocyte activation, contributing to symptom generation beyond direct mediator effects 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.